Iterum Therapeutics plc (NasdaqCM:ITRM) provided a general business update. Iterum plans to engage a financial advisor in the near-term to assist management and the Board in evaluating Iterum?s strategic alternatives.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.55 USD | -3.73% | 0.00% | -21.32% |
05-10 | Iterum Therapeutics plc Announces Executive Changes | CI |
04-29 | Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.32% | 25.66M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- ITRM Stock
- News Iterum Therapeutics plc
- Iterum Therapeutics Plans to Engage Financial Advisor to Evaluate Strategic Alternatives